Publication date: Feb 01, 2025
Significant concerns have been raised regarding the overuse of antibiotics among patients hospitalized for coronavirus disease 2019 (COVID-19) and the broad impact of the pandemic on antimicrobial stewardship in acute care. We sought to compare potentially unnecessary antibiotic prescribing over time among patients admitted with symptomatic COVID-19 and non-COVID-19 viral acute respiratory tract infections (ARTIs). We conducted a repeated cross-sectional analysis of the monthly antibiotic prescribing rate from March 2020 to December 2023 for COVID-19 admissions and from January 2019 to December 2023 for other viral ARTI admissions to 803 acute care hospitals in the United States that contributed data to the Premier Healthcare Database. Our primary outcome was the receipt of ≥1 dose of an antibiotic during the first 5 days of the admission. Secondary outcomes included days and duration of antibiotic therapy. This study included 513 698 COVID-19 and 106 932 non-COVID-19 viral ARTI admissions from March 2020 to December 2023. At the onset of the pandemic, >80% of patients admitted for COVID-19 received antibiotics, and antibiotic prescribing for other viral ARTIs increased to nearly 70%. Antibiotic prescribing for these viral infections declined over time, with prescribing for COVID-19 stabilizing around 35% in 2022-2023 and prescribing for other viral ARTIs returning to 2019 seasonal patterns in 2023, with average monthly prescribing around 50%. Despite improvements since the early part of the COVID-19 pandemic, potentially unnecessary antibiotic prescribing for inpatients with COVID-19 and non-COVID-19 viral ARTIs remains an important antibiotic stewardship target.
Open Access PDF
| Concepts | Keywords |
|---|---|
| Coronavirus | antibiotic stewardship |
| Covid | COVID-19 |
| Seasonal | pandemic |
| Therapy | prescribing trends |
| respiratory viruses |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Coronavirus Disease 2019 |
| disease | MESH | Respiratory Infections |
| disease | MESH | viral infections |
| disease | MESH | Infectious Diseases |
| disease | MESH | Emergency |
| pathway | REACTOME | Reproduction |
| pathway | REACTOME | Translation |
| disease | IDO | site |
| drug | DRUGBANK | Coenzyme M |
| disease | MESH | infections |
| disease | MESH | bacterial infections |
| disease | MESH | adverse drug events |
| disease | MESH | colitis |
| disease | MESH | dysbiosis |
| disease | MESH | coinfections |
| disease | MESH | uncertainty |
| disease | IDO | algorithm |
| disease | MESH | influenza |
| disease | MESH | parainfluenza |
| disease | MESH | urinary tract infection |
| disease | MESH | sinusitis |
| disease | IDO | infection |
| drug | DRUGBANK | Esomeprazole |
| disease | MESH | hypertension |
| disease | MESH | obesity |
| disease | MESH | Anemias |
| disease | MESH | nutritional deficiencies |
| disease | MESH | Depression |
| disease | MESH | complications |
| disease | MESH | Heart failure |
| disease | MESH | Hypothyroidism |
| disease | MESH | Acidosis |
| disease | MESH | diabetes mellitus |
| disease | MESH | Etiology |